Observation on the Therapeutic Effect of Bushen Jianpi Formula in Treating Type 2 Diabetes Mellitus Complicated with Non-alcoholic Fatty Liver Disease
10.13359/j.cnki.gzxbtcm.2025.11.012
- VernacularTitle:补肾健脾方治疗2型糖尿病合并非酒精性脂肪肝病的疗效观察
- Author:
Yan LI
1
;
Feng LIU
;
Jiewen ZHANG
;
Jing LIN
;
Bing JI
Author Information
1. 广州中医药大学,广东 广州 510006
- Keywords:
Bushen Jianpi Formula;
metformin;
type 2 diabetes mellitus(T2DM);
non-alcoholic fatty liver disease(NAFLD);
spleen-kidney deficiency type;
glycolipid metabolism;
liver function;
insulin resistance
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2025;42(11):2705-2713
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy of Bushen Jianpi Formula(BSJPF)in treating type 2 diabetes mellitus(T2DM)complicated with non-alcoholic fatty liver disease(NAFLD)of spleen-kidney deficiency type.Methods Seventy-two patients with T2DM complicated with NAFLD of spleen-kidney deficiency type admitted to Clifford Hospital from June 2023 to September 2024 were randomized into treatment group(n=36,receiving lifestyle intervention+metformin+BSJPF)and control group(n=36,lifestyle intervention+metformin alone)for 12 weeks.TCM syndrome scores,liver function markers,ultrasonographic grading of fatty liver,glycolipid metabolic parameters were observed,and the clinical efficacy and safety were assessed.Results(1)Regarding dropouts,during the study,2 patients in the treatment group dropped out,while none occurred in the control group.Ultimately,34 patients in the treatment group and 36 in the control group completed efficacy evaluation.(2)In terms of clinical efficacy,after 12 weeks of treatment,the total effective rate was 88.24％(30/34)in the treatment group versus 66.67％(24/36)in the control group.Intergroup comparison(by chi-square test)showed significantly superior efficacy in the treatment group(P＜0.05).(3)For liver function indicators,after treatment,serum alanine aminotransferase(ALT),aspartate aminotransferase(AST),and γ-glutamyl transpeptidase(GGT)levels decreased significantly in both groups compared to those before treatment(P＜0.05),with substantially greater reduction in the treatment group(P＜0.05).(4)Regarding fatty liver ultrasound grading,both groups showed improvement after treatment(P＜0.05),with significantly greater enhancement in the treatment group(P＜0.05).(5)For glucose-lipid metabolism markers,both groups exhibited decreased fasting blood glucose(FBG),2-hour postprandial glucose(2hPG),glycated hemoglobin(HbA1c),fasting insulin(FINS),insulin resistance index(HOMA-IR),total cholesterol(TC),triglycerides(TG),and low-density lipoprotein cholesterol(LDL-C)levels(P＜0.05),with treatment group showing markedly greater reductions(P＜0.05);both groups demonstrated increased high-density lipoprotein cholesterol(HDL-C)levels(P＜0.05),with treatment group showing significantly greater elevation(P＜0.05).(6)In TCM syndrome score assessment,both groups showed reduced scores after treatment(P＜0.05),with treatment group demonstrating significantly greater improvement(P＜0.05).(7)Regarding safety,routine blood/urine/stool tests,renal function indicators,and electrocardiograms remained normal in both groups.The adverse reaction rate was 2.94％(1/34)in treatment group versus 5.56％(2/36)in control group,with no statistically significant difference between groups(P＞0.05).Conclusion BSJPF combined with metformin demonstrates superior efficacy to metformin alone for patients with T2DM complicated with NAFLD of spleen-kidney deficiency type.It is effective in relieving clinical symptoms,enhancing TCM syndrome efficacy,improving liver enzymes,fatty liver grading and insulin resistance,and regulating glycolipid metabolism.
